Clinical trials
Resistance clinical trials
Below are recruiting resistance clinical trials, each written for real people, not researchers. We’re tracking 1,198 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07878897Recruiting
Care evaluation for adults with self-harm and eating disorders
This study evaluates a specialized national care program for adults with severe self-harm or eating disorders. Participation involves interviews or questionnaires to help improve care for others with similar struggles.
StockholmAges 18 years+ - NCT06586957RecruitingPhase 1
Study of NKT3964 for advanced solid tumors
This trial tests an experimental drug called NKT3964 for people with certain advanced cancers that have stopped responding to standard treatments. It aims to see if the drug can shrink tumors or slow their growth.
Little Rock, ArkansasAges 19 years+ - NCT07434986Recruiting
Overnight brain stimulation for temporal lobe epilepsy
This study tests whether a gentle magnetic device applied overnight can help reduce seizures in people with temporal lobe epilepsy. You'll stay in a sleep lab for one night while we monitor your brain waves and sleep.
Durham, North CarolinaAges 18–70 - NCT07546253Recruiting
Tracking outcomes for brain ablation in drug-resistant epilepsy
This trial is a registry that tracks real-world outcomes for people with drug-resistant epilepsy who are treated with the NeuroOne OneRF ablation system. Participants receive a standard procedure (RF ablation) and their health data is collected to help improve future care.
Miami, FloridaAges Any age - NCT07667400RecruitingPhase 1/Phase 2
Docetaxel plus SX-682 for advanced head and neck or prostate cancer
This trial studies a combination of the chemotherapy drug docetaxel and an investigational drug called SX-682 for people with certain advanced head and neck cancers or prostate cancer. The goal is to see if the combination is safe and effective.
Bethesda, MarylandAges 18–120 - NCT07770711Recruiting
Inositol and metformin with different diets for PCOS
This study compares two diet plans (Mediterranean and low-carb) along with the supplements inositol and metformin, to see which works better for weight and blood sugar control in women with PCOS and insulin resistance. It may help you manage PCOS symptoms and improve your body's response to insulin.
Diyarbakır, DiyarbakırAges 20–40 - NCT07876479Recruiting
Comparing kidney nerve treatment times for high blood pressure
This study tests whether the length of time used for a kidney nerve treatment (renal denervation) affects how well it lowers blood pressure. It may help people whose blood pressure is still high despite taking medications.
ShanghaiAges 20–80 - NCT06970457Recruiting
Exercise, body fat, and hormones in men
This study investigates how exercise affects sex hormones in men with different body types. Participants will engage in a supervised exercise program to see how it interacts with body composition.
Stillwater, OklahomaAges 18–79 - NCT06007404Recruiting
Understanding metabolism and inflammation in teens
This study looks at how metabolism and inflammation relate to diabetes risk in teenagers. It may help researchers understand why some teens develop type 2 diabetes.
Ann Arbor, MichiganAges 14–18 - NCT07226986RecruitingPhase 1/Phase 2
Study of AMO959 with Lutetium-177 and ARPI for prostate cancer
This trial tests a new combination therapy for men with advanced prostate cancer that has spread and is no longer responding to hormone therapy. It combines an experimental drug (AMO959) with a targeted radiation treatment (Lutetium-177) and a standard hormone therapy to see if it helps control the cancer.
Los Angeles, CaliforniaAges 18 years+ - NCT07824349RecruitingPhase 1
JUR-003 for metastatic prostate cancer
This trial tests an experimental drug called JUR-003 in people with prostate cancer that has spread to other parts of the body. It aims to see if the drug can shrink tumors or slow the cancer's growth.
Grand Rapids, MichiganAges 18 years+ - NCT07677267Recruiting
Study of treatment patterns and outcomes for advanced prostate cancer patients
This study looks at real-world data from patients with metastatic castration-resistant prostate cancer (mCRPC) who have already used certain treatments, including a newer drug called lutetium-177 PSMA-617. It aims to understand how these treatments work and what happens to patients over time.
East Hanover, New JerseyAges 18–115 - NCT07214779RecruitingPhase 3
New drug vs chemo for platinum-resistant ovarian cancer
This study tests a new drug (INCB123667) given as a pill, compared to standard chemotherapy, for people whose ovarian cancer has stopped responding to platinum-based treatments and whose tumor has high levels of a protein called Cyclin E1. The goal is to see if the new drug works better than standard chemo for this specific type of cancer.
Anchorage, AlaskaAges 18 years+ - NCT07286266RecruitingPhase 3
Testing a new drug for platinum-resistant ovarian cancer
This phase 3 trial tests a new drug, mocertatug rezetecan, against standard treatments for ovarian cancer that no longer responds to platinum chemo. It's for people who have had 1 to 4 prior therapies and may offer a new option if you haven't tried all standard treatments yet.
Randwick, New South WalesAges 18 years+ - NCT07344311RecruitingPhase 1
CAR-T cell therapy for advanced prostate cancer
This trial tests a new immunotherapy called A-CAR032, which uses your own immune cells to attack prostate cancer cells. It is for men with metastatic castration-resistant prostate cancer that has progressed after other treatments.
Beijing, Beijing MunicipalityAges 18 years+ - NCT03591276RecruitingPhase 1/Phase 2
Doxorubicin plus pembrolizumab for hormone-resistant breast cancer
This Phase 1b/2 trial tests a combination of pegylated liposomal doxorubicin and pembrolizumab for breast cancer that no longer responds to hormone treatment. It aims to see how well the combination works and how safely it can be given to patients with advanced disease.
JerusalemAges 18 years+ - NCT03784651Recruiting
How breast cancer treatment changes metabolism and bone
This study looks at how standard breast cancer treatments affect your body’s metabolism and bones in postmenopausal people with early-stage breast cancer. It may help doctors better predict and prevent bone and metabolic side effects from treatment.
Copenhagen, DanmarkAges 50–70 - NCT05074732Recruiting
Study of forensic mental health admissions after a service move
This study looks at all adult admissions to Ireland’s National Forensic Mental Health Service during a specific time window. It may help improve how the new forensic service at Portrane runs in the future.
DublinAges 18 years+ - NCT02947503RecruitingPhase 3
Metformin for gestational diabetes in pregnancy outcomes
This study tests whether taking metformin during pregnancy improves outcomes for people with gestational diabetes. It may help with pregnancy health and baby outcomes compared with the study’s other diabetes care plan.
GroningenAges 18–45 - NCT05354375RecruitingPhase 1
PSMA-targeted CAR-T cell therapy for resistant prostate cancer
This Phase 1 study tests whether lab-made immune cells (CAR-T) that target PSMA can treat prostate cancer that keeps growing despite hormone treatment. It may help people whose disease no longer responds to standard endocrine (hormone-blocking) therapy.
Xuzhou, JiangsuAges 18–75 - NCT05307367Recruiting
Study exercise and body muscle changes in advanced lung cancer
This study looks at why cancer can cause loss of muscle in people with advanced non–small cell lung cancer, and whether exercise can improve or explain those muscle changes. You may be asked to do physical testing and answer questionnaires while receiving standard palliative cancer treatment.
Copenhagen, DKAges 18–100 - NCT05459090Recruiting
Study of how brain “brakes” work in drug-resistant temporal epilepsy
This study looks at how the brain’s natural “braking” system works in people with drug-resistant temporal lobe epilepsy. It may help researchers better understand the condition in order to improve future treatments.
Pozzilli, IserniaAges Any age - NCT05627960RecruitingPhase 1
Testing an antibody drug for advanced solid cancers
This Phase 1 study tests AG01, an antibody that targets a cancer protein called GP88, in people with advanced solid tumors. The goal is to find safe doses and learn whether it can help certain cancers.
Baltimore, MarylandAges 18 years+ - NCT05636605Recruiting
Study lung cancer biology and why immunotherapy stops working
This study looks at lung cancer tissue and immune system changes to understand how and why immunotherapy resistance develops. It may help researchers find better ways to make immunotherapy work longer for future patients.
Yiwu, ZhejiangAges 18–80
Hear when a new Resistance trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for resistance?
- Yes. Clin2 currently lists 1,198 recruiting resistance studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a resistance trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a resistance trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.